- Home
- WFG vs RLAY Comparison
WFG vs RLAY Comparison
Compare WFG & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | RLAY |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WFG | RLAY |
|---|---|---|
| Price | $69.68 | $19.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $89.50 | $19.50 |
| AVG Volume (30 Days) | 212.6K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $10.26 | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $57.34 | $3.15 |
| 52 Week High | $76.99 | $20.79 |
Technical Indicators
Market Signals| Indicator | WFG | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | N/A |
| Support Level | $63.81 | N/A |
| Resistance Level | $72.72 | N/A |
| Average True Range (ATR) | 2.37 | 0.00 |
| MACD | 0.36 | 0.00 |
| Stochastic Oscillator | 98.55 | 0.00 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.